GM-CSF-adjuvanted DNA/MVA vaccine: Phase I started

GeoVax began the double-blind, placebo-controlled, dose-escalation, U.S. Phase I HVTN 094 trial to evaluate its GM-CSF-adjuvanted DNA/MVA vaccine in 48 healthy volunteers. The trial is sponsored by th...